We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Monday
May 18
15:15 - 16:30
Poster Area
Urological cancer
Poster Highlights
Clinical
Integrating PSMA Radioligand Therapy with Pelvic Radiotherapy for Men with PSMA detected Oligorecurrent Pelvic Nodal Metastases of Prostate Cancer
Tee Lim, Australia
-386
Precision radiotherapy in intermediate-risk prostate cancer: role of dose escalation and androgen deprivation therapy
Cem Onal, Turkey
-977
Outcomes comparison between intermediate and high-risk prostate cancer, using the NCCN classification; Long term results based on 2 phase III trials
Abdenour Nabid, Canada
-1058
Long-term PSA kinetics after SBRT and LDR brachytherapy in low- and favorable-intermediate risk prostate cancer
Maria Cerrolaza, Spain
-1060
Biomechanistic modeling of PSA dynamics describes personalized prostate cancer response to radiotherapy and androgen deprivation therapy
Guillermo Lorenzo Gomez, Spain
-1117
Redefining PSA kinetics after prostate cancer radiotherapy: The prognostic significance of PSA bounces
Mariana Borras-Osorio, USA
-1148
Deaths due to second malignancies in localised prostate cancer: long term prospective data from two phase III trials
Abdenour Nabid, Canada
-1151
Stereotactic re-irradiation for intraprostatic recurrences: outcomes, toxicity, and proposal of a prognostic score
Yazid ABOU EL FATTAH, France
-1257
Need for Pelvic Inclusion with Hypofractionated Regimens in Muscle-Invasive Bladder Cancer: An Institutional Experience with Real-World Patients
Ariel Gómez Palacios, Argentina
-1269
post-void residual urinary volume is a predictor of acute urinary toxicity in stereotactic body radiation therapy for prostate cancer
Enrico Raggi, Italy
-1286
Predictive value of prostate volume and baseline urinary function across three SBRT fractionation regimens
Valeria Faccenda, Italy
-1510
Stereotactic Body Radiotherapy for Localized Prostate Cancer: Two-Year Tolerability and Biochemical Control in a Multicenter Spanish Cohort.
Daniela Gonsalves Pieretti, Spain
-396
Dose-response associations in pelvic substructures following Single-Dose Ablative Radiotherapy for prostate cancer: an ABRUPT trial post hoc analysis
Valeria Faccenda, Italy
-1543
Classical or moderately hypofractionated irradiation of pelvic nodes with prostate boost in high-very high risk prostate cancer: prospective studies.
Sergey Novikov, Russian Federation
-1718
PSMA PET-guided local and metastatic directed radiation therapy for de novo oligometastatic prostate adenocarcinoma: feasibility and early outcomes
Shikha Goyal, India
-1897
Intraprostatic Lesion Boost Enhances PSA Kinetics in High PI-RADS Prostate Cancer Treated with MR-Guided SBRT
Darren MC Poon, China, Hong Kong Special Administrative Region
-2002
Prospective Comparison of 5-Fraction SBPT and MR-Guided SBRT in High-Risk Prostate Cancer: One-Year Urinary Continence and Quality-of-Life Outcomes
Darren MC Poon, China, Hong Kong Special Administrative Region
-2059
Clinical outcomes of dose-escalated radiotherapy for muscle-invasive bladder cancer
Li Chan, Australia
-2061
Safety and Feasibility of 0.35T MR-Guided Adaptive SBRT in Localized Prostate Cancer: A Prospective Analysis
Abrahams Ocanto, Spain
-2123
Does Simultaneous Integrated Boost Improve Outcomes in Unfavorable Intermediate-Risk Prostate Cancer?
Cem Onal, Turkey
-2145
Dose–response for late urinary incontinence after prostate cancer radiotherapy integrating ?/? estimates, bladder volume effects, and patient factors
Gianluca Villa, Italy
-2159
Definitive Intensity-Modulated Radiotherapy for Upper Urothelial Carcinoma: A Single-Institution Retrospective Study
Yuki Mukai, Japan
-472
Initial Accrual in the phase III URONCOR 06-24 Trial on ADT Duration and Salvage Radiotherapy for Biochemical Recurrence
Abrahams Ocanto, Spain
-2507
Long-Term Efficacy and Safety of Salvage Postoperative Stereotactic Body Radiotherapy for the Prostate Bed
Sergey Novikov, Russian Federation
-2614
Oligoprogressive Renal Cell Carcinoma: When Medical Oncologists Vote on Radiotherapy : Insights from the AI-assisted Italian Delphi Consensus
Giulia Marvaso, Italy
-2756
External validation of models predicting sexual function 2 years after curative prostate cancer radiotherapy
Christian Jongen, The Netherlands
-2765
Synergistic Use of Stereotactic Body Radiotherapy and Immunotherapy in Advanced Renal Cell Carcinoma: Croatian Uro-Oncology Network Experience
Hrvoje Brčić, Croatia
-2869
Low rates of gynecomastia following neoadjuvant ADT combined with SBRT for localized prostate cancer
Sean Collins, USA
-3000
Stereotactic body radiotherapy for localized prostate cancer – 10-year follow-up results
Kristiina Vuolukka, Finland
-3282
Comparative Analysis of ¹?F-DCFPyL-PSMA vs ¹?F-PSMA-1007 PET/CT: Impact on Therapeutic Management and Change in Treatment Intent After PSMA Imaging
Francesco Amorelli, Spain
-3947
PSMA PET-positive local recurrences in the prostate bed region and their coverage based on clinical target volume delineation guidelines
Michael Keilholz, Germany
-476
Daily CBCT-based oART vs IGRT in localized prostate cancer: toxicity and quality of life in a prospective parallel-cohort study
Goda Kalinauskaite, Germany
-4009
Extreme hypofractionation is less lympho-toxic than moderate hypofractionaton after post-prostatectomy salvage radiotherapy
Marta Bottero, Italy
-4346
Machine Learning–Driven Prediction of Biochemical Failure After Salvage Radiotherapy for Prostate Cancer
Hrvoje Brčić, Croatia
-4665
PSMA PET/CT for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy: Is It Time to Review the Phoenix Criteria?
Rosario Mazzola, Italy
-4944
Rectal Spacer Mitigates Late GI Toxicity Independent of Adaptive Workflow in MR-Guided SBRT for Localized Prostate Cancer
Darren MC Poon, China, Hong Kong Special Administrative Region
-529
The association between acute, subacute, and late genitourinary quality of life with prostate SBRT
Li Chan, Australia
-655
Simultaneous MR-Guided SBRT to the Prostate Primary, Pelvis and Intraprostatic Lesion Boost in High-Risk Prostate Cancer: A Prospective Study
Darren MC Poon, China, Hong Kong Special Administrative Region
-683
Diagnostic Capability and Improved Clinical Management of 18F-DCFPyL-PSMA PET/CT in Occult Biochemical Recurrence of Prostate Cancer
Francesco Amorelli, Spain
-928
MRL guided adapted focal SABR for unifocal intermediate risk prostate cancer: interim analysis
Kianan Lim Joon, Australia
-934